Ditchcarbon
  • Customers
  1. Organizations
  2. Bavarian Nordic
Public Profile
Pharmaceutical Preparation Manufacturing
DK
updated 2 days ago

Bavarian Nordic

Company website

Bavarian Nordic A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach in the field of immunotherapy and vaccine development. Founded in 1994, the company has made significant strides in combating infectious diseases and cancer, with a strong operational presence across Europe and North America. Specialising in the development of live virus vaccines and immunotherapies, Bavarian Nordic's core products include the smallpox vaccine, IMVAMUNE®, and the cancer immunotherapy candidate, BN-Brachyury. These offerings are distinguished by their unique mechanisms and robust safety profiles, positioning the company as a key player in the biopharmaceutical industry. With a commitment to advancing public health, Bavarian Nordic has achieved notable milestones, including partnerships with global health organisations, solidifying its reputation as a trusted innovator in vaccine technology.

DitchCarbon Score

How does Bavarian Nordic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

44

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Bavarian Nordic's score of 44 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.

67%

Let us know if this data was useful to you

Bavarian Nordic's reported carbon emissions

In 2023, Bavarian Nordic reported total carbon emissions of approximately 10,682,000 kg CO2e, with Scope 1 emissions at about 4,364,000 kg CO2e and Scope 2 emissions at around 6,318,000 kg CO2e. The combined Scope 1 and 2 emissions totalled approximately 7,402,000 kg CO2e. This marks a significant increase from 2022, when total emissions were about 2,753,000 kg CO2e, with Scope 1 at approximately 1,765,000 kg CO2e and Scope 2 at about 988,000 kg CO2e. Bavarian Nordic has committed to achieving Net Zero emissions by 2050, in alignment with the Paris Agreement. In 2024, the company plans to define its carbon footprint reduction pathway, focusing on all scopes of emissions. This commitment reflects a proactive approach to climate action within the pharmaceutical and biotechnology sector. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. Bavarian Nordic's emissions data is self-reported and does not appear to be cascaded from a parent or related organization.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2017201820192020202120222023
Scope 1
992,000
000,000
000,000
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
1,686,000
0,000,000
0,000,000
0,000,000
0,000,000
000,000
0,000,000
Scope 3
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Bavarian Nordic's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Bavarian Nordic is in DK, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Bavarian Nordic is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Achillion Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Arrow Therapeutics, Ltd.

GB
Updated 7 days ago

Valneva

FR
•
Pharmaceutical Preparation Manufacturing
Updated about 3 hours ago

Emergent BioSolutions

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250731.5
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy